Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as maintenance therapy. The mechanisms of action of these agents is, in many ways, complementary, and crucially reliant on th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Michelle McMullen, Katherine Karakasis, Ainhoa Madariaga, Amit M. Oza
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2020-06-01
Serie:Cancers
Soggetti:
resistance mechanisms
platinum
PARP
ovarian cancer
homologous recombination
Accesso online:https://www.mdpi.com/2072-6694/12/6/1607
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi